



HAL
open science

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Celine Boschi, David Scheim, Audrey Bancod, Muriel Militello, Marion Le Bideau, Philippe Colson, Jacques Fantini, Bernard La Scola

► **To cite this version:**

Celine Boschi, David Scheim, Audrey Bancod, Muriel Militello, Marion Le Bideau, et al.. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects. *International Journal of Molecular Sciences*, 2022, 23 (24), pp.15480. 10.3390/ijms232415480 . hal-03959931

HAL Id: hal-03959931

<https://amu.hal.science/hal-03959931>

Submitted on 21 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Article

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Celine Boschi ¹, David E. Scheim ^{2,*} , Audrey Bancod ¹, Muriel Militello ¹, Marion Le Bideau ¹, Philippe Colson ¹ , Jacques Fantini ³ and Bernard La Scola ^{1,*}

¹ MEPHI, Aix-Marseille Université, Institut de Recherche Pour le Développement (IRD), Assistance Publique—Hôpitaux de Marseille (AP-HM), IHU Méditerranée Infection, 13005 Marseille, France
² US Public Health Service, Commissioned Officer, Inactive Reserve, Blacksburg, VA 24060, USA
³ INSERM UMR S 1072, Aix-Marseille Université, 13015 Marseille, France
* Correspondence: dschein@alum.mit.edu (D.E.S.); bernard.la-scola@univ-amu.fr (B.L.S.); Tel.: +1-540-3208013 (D.E.S.); +33-413732401 (B.L.S.)



Citation: Boschi, C.; Scheim, D.E.; Bancod, A.; Militello, M.; Bideau, M.L.; Colson, P.; Fantini, J.; Scola, B.L. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects. *Int. J. Mol. Sci.* **2022**, *23*, 15480. <https://doi.org/10.3390/ijms232415480>

Academic Editors: Malgorzata Kloc and Jacek Z. Kubiak

Received: 25 November 2022

Accepted: 3 December 2022

Published: 7 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Experimental findings for SARS-CoV-2 related to the glycan biochemistry of coronaviruses indicate that attachments from spike protein to glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells and endothelial cells are key to the infectivity and morbidity of COVID-19. To provide further insight into these glycan attachments and their potential clinical relevance, the classic hemagglutination (HA) assay was applied using spike protein from the Wuhan, Alpha, Delta and Omicron B.1.1.529 lineages of SARS-CoV-2 mixed with human RBCs. The electrostatic potential of the central region of spike protein from these four lineages was studied through molecular modeling simulations. Inhibition of spike protein-induced HA was tested using the macrocyclic lactone ivermectin (IVM), which is indicated to bind strongly to SARS-CoV-2 spike protein glycan sites. The results of these experiments were, first, that spike protein from these four lineages of SARS-CoV-2 induced HA. Omicron induced HA at a significantly lower threshold concentration of spike protein than the three prior lineages and was much more electropositive on its central spike protein region. IVM blocked HA when added to RBCs prior to spike protein and reversed HA when added afterward. These results validate and extend prior findings on the role of glycan bindings of viral spike protein in COVID-19. They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines, which use spike protein as the generated antigen.

Keywords: SARS-CoV-2; COVID-19; spike protein; hemagglutination; sialic acid; CD147; electrostatic charge; glycophorin A

1. Introduction

Key to the infectivity and morbidity of SARS-CoV-2 are glycans that protrude tangentially from 22 N-linked glycosylation sites on each monomer of its spike protein [1–5]. These N-glycans, several of which are capped with terminal sialic acid (SA) moieties, sweep back and forth across spike protein like windshield wipers, partially shielding it from antibody binding [1,2,6,7]. For SARS-CoV-2 and several other coronaviruses, these N-glycans serve as appendages for the virus to make its initial attachments to glycoconjugates on the host cell surface [1,8–13]. These glycoconjugates are abundantly distributed on the surfaces of host cells such as red blood cells (RBCs) [14,15], platelets [16] and endothelial cells [17] and confer an associated negative electrostatic potential, additionally facilitating attachments by positively charged SARS-CoV-2 spike protein prior to viral fusion to ACE2 for replication [8,18–20]. For endothelial cells of blood vessel linings, for example, the disparity between 28,000 SA-tipped CD147 receptors and 175 ACE2 receptors per cell [21]

provides a supporting indication of the role of glycans in widespread endothelial damage reported in COVID-19 patients [22,23].

The RBC has an especially dense surface distribution of SA, 35 million SA molecules per cell, arrayed on its sialoglycoprotein coating mainly as terminal residues of glycoprotein A (GPA) [14,15]. SA in its predominant human form, Neu5Ac, is the most common terminal residue of GPA on human RBCs, with the other terminal monosaccharides of GPA matching those on SARS-CoV-2 spike N-glycans [2,5]. Through attachments to viruses via this GPA surface coating, RBCs and other blood cells can serve a host defense role [14,24,25]; however, these RBC clumps can be vascularly obstructive to the host's detriment. Aggregates of RBCs have indeed been found in the blood of most [26,27] or a third [28] of COVID-19 patients in three clinical studies. In a study that examined the blood of hospitalized COVID-19 patients using immunofluorescence analysis, SARS-CoV-2 spike protein punctae were found on 41% of their RBCs [29]. In vitro, SARS-CoV-2 spike protein and pseudovirus attached to a nanoparticle array bearing SA derivatives [30]. Microarray detection techniques typically fail to detect these spike protein attachments to either SA [31] or CD147 [32], since they are formed through nanoscale multivalent bindings [1].

This hemagglutinating property of SARS-CoV-2 has important clinical consequences. First, with trillions of RBCs each circulating through narrow pulmonary capillaries about once per minute, even small, dynamically aggregating and disaggregating RBC clumps (as can form even in the absence of pathogens [33,34]) can impede RBC oxygenation. Peripheral ischemia, endothelial damage and vascular occlusion are indeed frequently observed in serious cases of COVID-19, as reviewed [1,23]. In COVID-19 patients, damaged endothelium of pulmonary capillaries is often observed adjoining relatively intact alveoli [35,36], while hypoxemia is manifested despite normal breathing mechanics [22,35,37–39]. These morbidities of COVID-19 parallel those of severe malaria, in which clumping of parasite-infected RBCs to other RBCs via SA terminal residues and endothelial cyto-adhesion also often result in fatal outcomes [1].

Although the blood cell types and processes entailed in clumping, clotting and vascular obstruction of COVID-19 are wide-ranging, virally induced hemagglutination (HA) is a central event that is amenable to in vitro study. The classic HA assay was used here to study this, using cell culture supernatants and SARS-CoV-2 trimeric spike protein. Indeed, SARS-CoV-2 spike protein mixed with human whole blood caused RBC aggregation [40], while spike protein from two other coronavirus strains also induced HA [41,42]. The HA assay can be applied further to study the HA-inhibitory effects of agents that bind to sites on spike protein, potentially shielding them from attachments to host cells. Several in silico studies [1] have found that the macrocyclic lactone ivermectin (IVM) binds with high affinity to subdomains on SARS-CoV-2 spike protein, including several glycosylated binding sites [43]. IVM achieved Nobel-prize-honored distinction for success against global parasitic scourges [44] but is of disputed efficacy in the treatment of COVID-19, as indicated, for example, by the disparity in the conclusions of this editorial [45] and its key cited meta-analysis [46].

The goals of this study were to determine whether principles of glycobiology as established for coronaviruses and in particular for SARS-CoV-2, can be validated using the classic HA assay, to test whether HA inhibition is achieved by an agent indicated to competitively bind to those glycans and to determine the comparative hemagglutinating potencies of the Wuhan virus and its Alpha, Delta and Omicron B.1.1.529 variants. The clinical relevance of testing HA induced by SARS-CoV-2 using spike protein rather than whole virus and the utility of additionally testing for HA inhibition via competitive glycan binding using IVM was suggested in an earlier study [1]. The differences in the electrostatic potential of the spike protein of these four variants were studied using molecular modeling and were related to their HA-inducing potencies as experimentally observed.

2. Results

2.1. Tests for Hemagglutination (HA) and for Its Inhibition and Reversal by IVM

In the HA experiment, for the Wuhan, Alpha and Delta lineages, we observed HA at a spike protein concentration of 1.06 ng/μL and above, but not below. For the Omicron spike protein, we observed HA at a minimum concentration of 0.13 ng/μL and above, but not below (Figures 1 and 2, Table 1).




Figure 1. Sample images of wells in which HA occurred (1; no teardrop visible) and HA did not occur (2; teardrop visible).




Figure 2. HA as induced by spike protein concentrations of 0.27, 0.53, 1.06 and 2.12 ng/μL for the Wuhan, Alpha and Delta strains of SARS-CoV-2, and at spike protein concentrations of 0.07, 0.13, 0.27 and 0.53 ng/μL for Omicron. Effects on reversal of HA are shown for IVM at concentrations of 1, 2, 4 and 8 μM added 30 min after RBCs and spike protein. Similar results were obtained for inhibition of HA by IVM (not pictured), with differences described in Section 2.1 and summarized in Table 1.

Table 1. Minimum concentrations of recombinant spike protein (ng/ μ L) needed to induce HA when added to RBC solution, and concentrations of IVM (μ M) needed to inhibit or reverse this induced HA. Tests to determine these values were each done in triplicate.

Variant	Minimum Spike Protein Concentration to Induce HA (ng/ μ L)	Highest Spike Protein Concentration Tested for HA (ng/ μ L)	Minimum IVM Concentration to Inhibit HA at Highest Spike Concentration (μ M)	Minimum IVM Concentration to Release HA at Highest Spike Concentration (μ M)
Wuhan	1.06	2.12	1	1
Alpha	1.06	2.12	1	1
Delta	1.06	2.12	1	2
Omicron	0.13	0.53	1	2

In the HA inhibition experiment, IVM added to 2.5% RBC solution to attain a concentration of 1 μ M at 30 min prior to spike protein partially inhibited HA, with HA observed at a spike protein concentration of 2.12 ng/ μ L for the Wuhan, Alpha and Delta, and of 0.27 ng/ μ L for the Omicron viral lineages. With IVM at 2 μ M, complete inhibition of HA is observed for the Wuhan, Alpha and Delta lineages. For Omicron, IVM at 4 μ M is needed to totally block HA.

In the HA reversal experiment, concentrations of IVM needed to reverse HA at the highest concentration of spike tested were 1 μ M and 2 μ M for the Wuhan/Alpha and Delta/Omicron viral lineages respectively.

HA was not observed with cell culture supernatants of any SARS-CoV-2 strain.

In the control experiments, RBCs alone did not exhibit HA. RBCs mixed with phosphate-buffered saline (PBS) likewise did not exhibit HA. The addition of IVM to 50 μ L of 2.5% RBCs to attain a concentration of 8 μ M did not cause hemolysis or induce HA. A solution of 2.5% DMSO and 97.5% water, the solvent for IVM, did not block or reverse HA (Figures 2 and 3).




Figure 3. Controls: (A) RBCs alone, (B) RBCs with PBS, (C) RBCs with PBS and IVM and (D) RBCs with PBS and DMSO. No HA is observed.

2.2. Western Blot and Quantification Analysis

The results for quantification analysis by Western blot of spike protein of the Wuhan SARS-CoV-2 strain in cell culture supernatants are presented in Figure 4. This shows that its spike concentration is below the concentration thresholds for the induction of agglutination. Indeed, for the supernatant of the Wuhan strain in cell culture at 48 h post viral infection, the concentration of N-glycosylated spike protein is approximately 0.7 ng/ μ L, which dilutes to half that concentration when added to wells, approximately three times lower than the minimum concentration 1.06 ng/ μ L of recombinant spike found to induce HA in the HA experiment described above.

2.3. Molecular Modeling

Since the surface of RBCs is electronegative due to a high expression of anionic SA in membrane proteins and gangliosides, we used molecular modeling simulations to study

the electrostatic surface potential of the spike proteins used in the present study. We focused our attention on the central area of the spike trimers, which is formed by the receptor binding domain (RBD) of each monomer. The electrostatic potential of the central area of the spike trimers increased exponentially from the Wuhan initial lineage to the Omicron variant (Figure 5, lower panel). This was caused by a progressive decrease in electronegative zones (colored in red) and a concomitant increase in electropositivity (blue zones). The increase was modest between Wuhan and Alpha, larger for Delta, and reached very high levels for Omicron. As depicted in the upper panel of Figure 5, these variations in net positive electric charge between the four SARS-CoV-2 strains considered here have implications for the induction of HA, since electropositivity mitigates the electrostatic repulsion between negatively charged RBC surfaces.




Figure 4. Quantification by Western blot analysis of spike protein in cell culture supernatants. Lines 1 and 2: cell culture supernatants infected with SARS-CoV-2, Wuhan strain, harvested at 24 and 48 h respectively. Line 3: non-infected cell culture supernatant. Lines 4, 5 and 6: recombinant SARS-CoV-2 spike protein at 2.25, 1.25 and 0.56 ng/ μ L respectively.




Figure 5. Electrostatic surface potential of SARS-CoV-2 spike trimers as denoted by color, positive in blue and negative in red. **Upper panel.** Under physiological conditions, RBCs maintain separation from each other due to a repulsive electric zeta potential between their negatively charged surfaces. The electropositive surface of spike protein neutralizes this zeta potential, allowing closer contacts between RBCs. **Lower panel.** For all variants, the electrostatic surface potential of the spike trimer is more electropositive in the central area formed by the RBD of each monomer. Quantitative analysis of the surface potential (in AU = arbitrary units) shows an exponential increase from the Wuhan to Omicron lineages.

3. Discussion

For all four SARS-CoV-2 lineages tested, Wuhan, Alpha, Delta and Omicron BA.1, spike protein mixed with human RBCs induced HA. This result provides an in vitro counterpart to the clumps of stacked RBCs (rouleaux) found, for example, in the blood of most [26,27] or a third [28] of COVID-19 patients in three clinical studies, and reinforces indications that such blood cell aggregation is key to the morbidities of this disease. HA-associated vascular obstruction in COVID-19 was further demonstrated in zebrafish embryos [47], which have capillary diameters [48] and blood cell glycosylation patterns [49] similar to those of humans. SARS-CoV-2 spike protein injected into a zebrafish embryo vein caused the formation of small RBC clumps and an associated reduction in blood flow velocity within 3–5 min after injection [47]. Also, in various in vivo or in vitro studies, SARS-CoV-2 spike protein S1 was found to cause endothelial, pulmonary and neuronal damage, as well as platelet-thrombi formation and microclots [40,50–52].

In addition to the glycan bindings reviewed above, electrostatic attraction could promote attachments between RBCs and SARS-CoV-2 spike protein and contribute to the observed induction of HA. As indicated here by molecular modeling simulations, the SARS-CoV-2 spike protein central region has a net positive charge, which yields an attractive force to the negatively charged RBC surface and also mitigates the repulsive electrostatic force between RBCs. This result is consistent with prior determinations of a net positive electrostatic potential of the SARS-CoV-2 spike protein [19,53]. Regardless of whether glycan bindings or electrostatic attraction is the predominant underlying force, the HA observed here suggests, more generally, that spike protein attachments to other cells such as platelets and endothelial cells may be implicated in COVID-19 morbidities, these two cells, like RBCs, having dense surface distributions of SA-tipped glycans [1] and corresponding negative surface charges [16,17]. These attachments can manifest clinically in damage to endothelial cells induced by virions or free spike protein, marked by traces of spike protein [23,35,51], and in the formation of fibrin-hardened clots that incorporate platelets, neutrophils and other blood cells [54], potentially seeded by RBC clumps.

The much stronger HA-inducing effect of the spike protein of the SARS-CoV-2 Omicron variant vs. the prior lineages tested here, with thresholds of concentration for HA induction of 0.13 ng/ μ L for Omicron vs. 1.06 ng/ μ L for the Wuhan, Alpha and Delta lineages, was an intriguing result. Under the hypothesis that RBC clumping underlies the morbidities of COVID-19, especially those related to diminished efficiency of RBC oxygenation, this finding appears paradoxical, since percentages of patients having respiratory distress or requirements for oxygen or mechanical ventilation were all sharply less for Omicron as compared with prior viral lineages [55]. Yet diminished pulmonary morbidities of Omicron can be explained by its less efficient replication compared with prior SARS-CoV-2 lineages in the lung parenchyma, encompassing the alveolar epithelium, in contrast to Omicron's faster replication in the bronchi [56,57]. The disruption of the alveolar-capillary barrier caused by a COVID-19 infection is a prime route by which the virus enters the bloodstream [58], so limited replication of Omicron in alveolar tissue would limit systemic serum viral loads and potential for associated RBC clumping as well.

Among the attributes of the Omicron variant that are of interest for further study is that although its overall electrostatic potential is more positive than for prior lineages, its N-terminal domain (NTD) is less positive [53,59,60]. Consistent with the greater HA-inducing activity of Omicron, however, its SA-binding affinity as predicted by molecular modeling is greater than for prior lineages [61]. It has also been proposed, again based upon in silico analysis, that decreased binding affinity of mutated residues on the Omicron spike protein to a cellular receptor implicated in thromboembolic and neurological complications of COVID-19, α 7nAChR, could also account for decreased morbidity of this viral variant [62].

IVM, an electrically neutral molecule [63], has been found in silico to attach with a strong affinity to 10 glycan binding sites on the spike protein of the Alpha through Delta variants [43], which suggests that competitive inhibition of spike protein attachments to host cell glycoconjugates could be its means of HA inhibition. IVM at concentrations of

1–2 μM for the four different viral lineages inhibited HA when added concurrently with spike protein and also reversed HA that had been induced by the prior addition of spike protein. This HA-reversal effect could account for sharp increases observed within 24 h after administration of IVM of pre-treatment depressed SpO₂ levels in severe COVID-19 patients, as summarized in Figure 6 below, which reproduces a figure from the most recent of three clinical studies reporting this effect [64]. In contrast to the sharp, rapid increases in SpO₂ levels observed in these studies, moderate and severe COVID-19 patients under standard care typically manifest decreasing SpO₂ values in tandem with increasing pulmonary CT abnormalities from the day of onset of disease symptoms through the second week following, as established in several studies that tracked SpO₂ values, pulmonary abnormalities, or both [65–71].

The inhibition of HA by IVM as reported here parallels the prevention of RBC clumping in zebrafish embryos by heparan sulfate, a glycosaminoglycan likewise indicated to strongly bind to SARS-CoV-2 spike protein [49,72], when co-injected with spike protein [49]. It is noteworthy that the scattered RBC clumps observed in this zebrafish embryo study, as with those observed in the blood of COVID-19 patients [26–28], are much smaller than the macroscopic-scale HA—clusters of extensively interlaced RBCs—observed in this study. It is therefore likely that smaller concentrations of spike protein and IVM would be required to, respectively, induce and reverse RBC clumps of clinical relevance. Thus, the peak plasma level of IVM of approximately 412 nM, as attained about four hours after a standard oral dose of 200–350 $\mu\text{g}/\text{kg}$ [1], appears to be in a range that could achieve clinical effects analogous to HA reversal observed in this study at IVM concentrations of 1–2 μM .

The HA-inducing activity of SARS-CoV-2 spike protein, which is especially potent for Omicron, raises questions as to potential risks for COVID-19 mRNA vaccines, which use spike protein as the generated antigen, even though serious adverse effects (AEs) linked to spike protein, such as myocarditis [73–75], are rare. Detectable levels of SARS-CoV-2 spike protein and S1 in serum or plasma have been found to persist for as long as 50 days following such vaccinations [76–78]. The possibility that spike protein migrating into the bloodstream could in rare cases prompt such HA-associated AEs is suggested, for example, by a study of 1006 subjects experiencing AEs after receiving a Pfizer/BioNTech or Moderna mRNA vaccination, which found a significant degree of RBC aggregation in the blood of 948 of those subjects [79]. These risks may be increased for younger age groups, with 301 adolescents of 13–18 years of age who received two doses of the BNT162b2 mRNA COVID-19 vaccine in one study having a 29.2% rate of cardiac AEs, ranging from tachycardia or palpitation to myopericarditis [80]. The investigators considered chest pain, which occurred at a 4% incidence, “an alarming side effect,” however, myopericarditis cases were mostly mild and temporary. The possibility that the increased HA-inducing activity of the Omicron spike protein might result in increased HA-associated AEs from Omicron booster vaccines can be ruled out by close vaccine safety monitoring to follow up on the animal testing on these booster vaccines performed to date [81].

Additional experiments of interest for follow-up to this study include microscopic detection to check for the initial formation of RBC clumping at spike protein concentrations lower than those which induce HA. Also, the zebrafish study described above [47] could be replicated using IVM instead of heparan sulfate as the blocking agent. Finally, HA could be tested as in this experiment but using RBCs supplemented with human serum albumin (HSA) at a physiological concentration. If IVM were to bind to spike protein glycans at the same molecular region as that which binds to HSA, that could significantly limit its HA-inhibitory effect, since 93% of IVM binds to serum proteins, mainly HSA, in blood [82], and 93% of IVM would then be rendered inactive for this effect. Conversely, if, IVM were to bind to spike protein glycans and HSA each at different regions, then HSA, a large molecule (molecular mass of 66.5 kDa, vs. 875.1 Da for IVM), could considerably boost the HA-inhibitory effect of IVM through steric interference.




Figure 6. Mean changes in oxygen saturation (SpO₂) for severe COVID-19 patients following treatments including or excluding IVM. Reproduced from Stone et al., 2022 [64] (CC-BY 4.0). Patients tracked over various time periods from each regimen were those with SpO₂ values all recorded on room air, having pre-treatment (day 0) values $\leq 93\%$. The y-axis value at day n is the mean of changes in SpO₂ values from day 0 to day n, with error bars designating 95% confidence intervals. • Thairu et al., 2022 [83,84]: 26 patients, median age 45, treated with varying combinations of lopinavir/ritonavir (Alluvia), remdesivir, azithromycin, and enoxaparin as well as zinc sulfate and vitamin C. • Babalola et al., 2021 [84,85]: 19 patients, median age 33, treated with IVM, zinc and vitamin C, with some also given azithromycin and hydroxychloroquine. • Hazan et al., 2021 [86]: 19 patients, median age 63, treated with IVM, doxycycline and zinc. • Stone et al., 2022 [64]: 34 patients, median age 56.5, treated with IVM, doxycycline and zinc.

4. Materials and Methods

4.1. Source and Preparation of Red Blood Cells

Red blood cells (RBCs) were provided by the “Establishment Français du Sang” (EFS) from blood bag donors qualified as “non-therapeutic blood bag” (Convention N°7828). Twenty milliliters of whole blood (with anticoagulant EDTA) were added to a fifty-milliliter conical tube and filled with thirty milliliters of PBS at pH = 7.2 before centrifugation at $800 \times g$ for 10 min. Then, the supernatant was discarded and replaced with fresh PBS. This procedure was again repeated twice. After the last centrifugation, RBCs were diluted in PBS at a final concentration of 2.5%. RBCs were then stocked for one week at 4 °C.

4.2. Spike Proteins Preparation

Recombinant spike proteins (BioServUK, Sheffield, UK) of these four following SARS-CoV-2 strains were used for this experiment: Wuhan, Alpha, Delta and Omicron BA.1 (BSV-COV-PR-33, BSV-COV-PR-65, BSV-COV-PR-97 and BSV-COV-OM-0.1, respectively). Four concentrations of spike protein were prepared for each of these viruses by diluting stock suspension in PBS. Spike protein of each viral strain was dissolved in PBS and added

to wells at final increasing concentrations of 0.27 ng/ μ L, 0.53 ng/ μ L, 1.06 ng/ μ L and 2.12 ng/ μ L for the Wuhan, Alpha and Delta lineages, and of 0.07 ng/ μ L, 0.13 ng/ μ L, 0.27 ng/ μ L and 0.53 ng/ μ L for the Omicron variant.

4.3. Cells and SARS-CoV-2 Strains Preparation

Vero E6 cells (ATCC-CRL-1586) were cultured as in previously described conditions [87–89] in medium (MEM, Gibco, Gaithersburg, MD, USA) with 2 mM L-glutamine and 10% fetal bovine serum (FBS) at 37 °C in a 5% CO₂ incubator. We infected Vero E6 with four viral strains genotyped by whole genome next-generation sequencing (NGS) as belonging to: Pangolin lineage B.1.1 [90] (the first major lineage following the Wuhan genotype that circulated during the first epidemic period in France, designated as “Wuhan”) and three variants: Alpha (B.1.1.7), Delta (B.1.617.2) and Omicron BA.1 (B.1.1.529). Culture supernatants were harvested 24 h post-viral infection and then passed through 0.22 μ M pore-sized filters (Merck Millipore, Carrigtwohill, Ireland) to remove cells and debris and obtain viral suspension for experiments.

4.4. Western Blot and Quantification Analysis

Supernatants from Wuhan SARS CoV-2 infected cells prepared as described above or uninfected cells and commercial spike were lysed with 2 \times Laemmli Sample Buffer (#1610737, Bio-Rad, Hercules, CA, USA) with DTT (#EU0006-B, Euromedex, Souffelweyheim, France) added as reducing agent and then heated at 95 °C for 5 min. Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (Laemmli, 1970) and Western-blotted on a nitrocellulose membrane. After 1 h of saturation in 5% nonfat dry milk with 0.3% Tween-20 in PBS, the membrane was incubated overnight with SARS/SARS-CoV-2 Coronavirus Spike Protein (subunit 1) rabbit polyclonal antibody (Thermo Fisher Scientific, Illkirch-Graffenstaden, France) at a dilution of 1:1000 in the same buffer as for saturation. After this first incubation, the membrane was washed for 10 min three times in PBS 1X-Tween buffer and then incubated for 1 h at room temperature with peroxidase-labeled anti-rabbit donkey antibody (#NIF 824 ECL Rabbit IgG, HRP-linked whole Ab, Sigma-Aldrich Life Science, Burlington, MA, USA) diluted in saturation buffer at 1:1000. After this second incubation, the membrane was rinsed for 10 min three times in PBS 1X-Tween buffer before ECL (Western Blotting Substrate, # W1001 Promega, Madison, WI, USA) revelation by image acquisition with the Fusion Fx chemiluminescence imaging system (Vilber Lourmat, Marne-la Vallée, France). Quantification in each well was calculated by measuring band intensities using ImageQuant TL Version 7.0 analysis software (GE Healthcare, Buc, Yvelines, France). Protein markers (New England Biolabs, #P7719S) were used for molecular mass determination.

4.5. IVM Preparation

IVM was supplied by Sigma Aldrich (St Quentin Fallavier, France). Stock solution was diluted in 2.5% of DMSO and 97.5% of water. IVM, 20 μ L in volume, was added in designated wells to reach final concentrations of 1, 2, 4 and 8 μ M, as specified.

4.6. Tests for Hemagglutination (HA) and for Its Inhibition and Reversal by IVM

Three sets of experiments were performed to test for HA induced by SARS-CoV-2 spike protein and then for HA inhibition and reversal by IVM. To test for HA, using a 96 micro-well plate, 50 μ L of 2.5% RBCs in PBS was added to wells together with 62 μ L of diluted spike proteins at specified concentrations. An additional 20 μ L of PBS was added to attain the same total fluid volume as used in the IVM inhibition and reversal experiments. This mixture was let sit for 30 min at room temperature under gentle agitation. Then, the plate was tilted for at least 30 s, after which, if HA had not occurred a teardrop could be observed at the bottom of the well consisting of settled RBCs (Figure 1). This teardrop was not observed if HA had occurred, i.e., if a network of linked, agglutinated RBCs had formed, as described previously [91]. To test for inhibition of HA by IVM, 50 μ L of RBCs

were mixed with 20 μL of IVM at specified concentrations ranging from 1–8 μM and let sit for 30 min at room temperature under gentle agitation. Then 62 μL of spike protein was added at specified concentrations, wells were let sit for an additional 30 min at room temperature under gentle agitation, and HA was determined as above. Finally, to test for reversal of HA by IVM, 50 μL of RBCs were mixed with 62 μL of spike proteins for 30 min to determine HA as above. Then 20 μL of IVM were added at specified concentrations, wells were let sit for an additional 30 min at room temperature under gentle agitation and then the plate was tilted at least 30 s and wells were rechecked for HA as described above.

The following control experiments were performed. Fifty microliters of RBCs were deposited alone in the wells to check their absence of agglutination. Twenty microliters of PBS were added to fifty microliters of RBCs to verify the absence of HA. The potential for induction of HA by IVM was tested by adding it at the highest concentration used (8 μM) to 50 μL of 2.5% RBCs. In order to test whether DMSO blocked or reversed HA, we also performed the HA inhibition and reversal experiments described above using the solvent for IVM, 2.5% DMSO and 97.5% water, but without IVM.

The HA experiment was then done with viral suspensions for each viral strain by adding to the wells the same volume of viral supernatant as for commercial spike suspensions.

Each experiment was done in triplicate.

4.7. Molecular Modeling Simulations

A complete structure of the reference spike protein was generated from the original 20B strain (pdb: 7bnm) as previously described [92]. All gaps in the pdb file were fixed by inserting the missing amino acids with the protein structure prediction service Robetta [<https://robetta.bakerlab.org/>, accessed on 3 November 2022] [53,93]. This source file model was used to introduce the specific mutational profiles of the indicated Alpha, Delta and Omicron variants with the MUTATE tool of Swiss-PdbViewer [53,94]. Trimeric structures in the closed pre-fusion conformation were constructed with Swiss-PdbViewer by homology with a reference model (pdb: 6VSB). All structures were then submitted to several rounds of energy minimization with the Polak–Robière algorithm [88]. The electrostatic surface potential of the spike trimers was analyzed with Molegro and quantified with ImageJ software as described previously [92].

5. Conclusions

Spike protein from four lineages of SARS-CoV-2 induced HA in human RBCs, which supports other indications that spike protein-induced RBC clumping, as well as viral attachments to other blood cells and endothelial cells, may be key to the morbidities of COVID-19. IVM, a macrocyclic lactone indicated to bind strongly to multiple glycan sites on SARS-CoV-2 spike protein, blocked HA when added to RBCs prior to spike protein and reversed HA when added afterward, which suggests therapeutic options for COVID-19 treatment using this drug or other competitive glycan-binding agents. The Omicron B.1.1.529 variant had significantly greater HA-inducing activity than the three prior lineages tested, which may relate to the findings from molecular modeling that the electrostatic charge of the central region of its spike protein was considerably more positive than for those of the prior lineages and, from a prior study, that its SA-binding affinity is greater than for prior lineages [61]. Whether increased risks of rare HA-associated serious AEs for Omicron booster vaccines might be correspondingly increased as compared with those for legacy mRNA COVID vaccines can be ruled out by close vaccine safety monitoring to follow up on the animal testing on these booster vaccines performed to date.

Author Contributions: Conceptualization, D.E.S., J.F. and B.L.S.; methodology, J.F. and B.L.S.; validation, C.B., P.C., J.F. and B.L.S.; formal analysis, C.B. and B.L.S.; investigation, A.B., M.M. and M.L.B.; writing—original draft preparation, D.E.S., C.B., J.F. and B.L.S.; writing—review and editing, P.C.; supervision, J.F. and B.L.S.; project administration, B.L.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the French Government under the “Investments for the Future” program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU-03.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors are grateful to Barry Dancis for close review and editing of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

ACE2	angiotensin converting enzyme 2
CD147	cluster of differentiation 147 protein, encoded by the BSG gene
COVID-19	coronavirus disease 2019
GPA	glycophorin A
NTD	N-terminal domain
PBS	phosphate-buffered saline
RBC	red blood cell
RBD	receptor binding domain
RCT	randomized clinical trial
SA	sialic acid
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2

References

1. Scheim, D.E. A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody. *Int. J. Mol. Sci.* **2022**, *23*, 2558. [[CrossRef](#)]
2. Chen, W.; Hui, Z.; Ren, X.; Luo, Y.; Shu, J.; Yu, H.; Li, Z. The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 Coronavirus. *bioRxiv* **2020**. [[CrossRef](#)]
3. Guo, W.; Lakshminarayanan, H.; Rodriguez-Palacios, A.; Salata, R.A.; Xu, K.; Draz, M.S. Glycan Nanostructures of Human Coronaviruses. *Int. J. Nanomed.* **2021**, *16*, 4813–4830. [[CrossRef](#)] [[PubMed](#)]
4. Shajahan, A.; Supekar, N.T.; Gleinich, A.S.; Azadi, P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. *Glycobiology* **2020**, *30*, 981–988. [[CrossRef](#)] [[PubMed](#)]
5. Gao, C.; Zeng, J.; Jia, N.; Stavenhagen, K.; Matsumoto, Y.; Zhang, H.; Li, J.; Hume, A.J.; Mühlberger, E.; van Die, I.; et al. SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. *bioRxiv* **2020**. [[CrossRef](#)]
6. Sikora, M.; von Bülow, S.; Blanc, F.E.C.; Gecht, M.; Covino, R.; Hummer, G. Computational epitope map of SARS-CoV-2 spike protein. *PLoS Comput. Biol.* **2021**, *17*, e1008790. [[CrossRef](#)]
7. Choi, Y.K.; Cao, Y.; Frank, M.; Woo, H.; Park, S.-J.; Yeom, M.S.; Croll, T.I.; Seok, C.; Im, W. Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane. *J. Chem. Theory Comput.* **2021**, *17*, 2479–2487. [[CrossRef](#)]
8. Koehler, M.; Delguste, M.; Sieben, C.; Gillet, L.; Alsteens, D. Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans. *Annu. Rev. Virol.* **2020**, *7*, 143–165. [[CrossRef](#)]
9. Fantini, J.; Di Scala, C.; Chahinian, H.; Yahji, N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. *Int. J. Antimicrob. Agents* **2020**, *55*, 105960. [[CrossRef](#)]
10. Ströh, L.J.; Stehle, T. Glycan Engagement by Viruses: Receptor Switches and Specificity. *Annu. Rev. Virol.* **2014**, *1*, 285–306. [[CrossRef](#)]
11. Morniroli, D.; Giannì, M.L.; Consales, A.; Pietrasanta, C.; Mosca, F. Human Sialome and Coronavirus Disease-2019 (COVID-19) Pandemic: An Understated Correlation? *Front. Immunol.* **2020**, *11*, 1480. [[CrossRef](#)] [[PubMed](#)]
12. Neu, U.; Bauer, J.; Stehle, T. Viruses and sialic acids: Rules of engagement. *Curr. Opin. Struct. Biol.* **2011**, *21*, 610–618. [[CrossRef](#)] [[PubMed](#)]
13. Nguyen, L.; McCord, K.A.; Bui, D.T.; Bouwman, K.M.; Kitova, E.N.; Elaish, M.; Kumawat, D.; Daskhan, G.C.; Tomris, I.; Han, L.; et al. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. *Nat. Chem. Biol.* **2022**, *18*, 81–90. [[CrossRef](#)] [[PubMed](#)]
14. Baum, J.; Ward, R.H.; Conway, D.J. Natural selection on the erythrocyte surface. *Mol. Biol. Evol.* **2002**, *19*, 223–229. [[CrossRef](#)] [[PubMed](#)]
15. Aoki, T. A Comprehensive Review of Our Current Understanding of Red Blood Cell (RBC) Glycoproteins. *Membranes* **2017**, *7*, 56. [[CrossRef](#)] [[PubMed](#)]
16. Seaman, G.V.F. Electrochemical features of platelet interactions. *Thromb. Res.* **1976**, *8*, 235–246. [[CrossRef](#)] [[PubMed](#)]

17. Strilić, B.; Eglinger, J.; Krieg, M.; Zeeb, M.; Axnick, J.; Babál, P.; Müller, D.J.; Lammert, E. Electrostatic Cell-Surface Repulsion Initiates Lumen Formation in Developing Blood Vessels. *Curr. Biol.* **2010**, *20*, 2003–2009. [CrossRef]
18. Boulant, S.; Stanifer, M.; Lozach, P.-Y. Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis. *Viruses* **2015**, *7*, 2794–2815. [CrossRef]
19. Hassanzadeh, K.; Perez Pena, H.; Dragotto, J.; Buccarello, L.; Iorio, F.; Pieraccini, S.; Sancini, G.; Feligioni, M. Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms. *ACS Chem. Neurosci.* **2020**, *11*, 2361–2369. [CrossRef]
20. Pawłowski, P.H. Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants. *Infect. Drug Resist.* **2021**, *14*, 5099–5105. [CrossRef]
21. Ahmetaj-Shala, B.; Vaja, R.; Atanur, S.S.; George, P.M.; Kirkby, N.S.; Mitchell, J.A. Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells. *JACC Basic Transl. Sci.* **2020**, *5*, 1111–1123. [CrossRef] [PubMed]
22. Huertas, A.; Montani, D.; Savale, L.; Pichon, J.; Tu, L.; Parent, F.; Guignabert, C.; Humbert, M. Endothelial cell dysfunction: A major player in SARS-CoV-2 infection (COVID-19)? *Eur. Respir. J.* **2020**, *56*, 2001634. [CrossRef] [PubMed]
23. Scheim, D.E. From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, then Clot Blood Cells in Pulmonary and Systemic Microvasculature. Available online: <https://osf.io/sgdj2> (accessed on 17 October 2022).
24. De Back, D.Z.; Kostova, E.; Klei, T.; Beuger, B.; van Zwieten, R.; Kuijpers, T.; Juffermans, N.; van den Berg, T.; Korte, D.; van Kraaij, M.; et al. RBC Adhesive Capacity Is Essential for Efficient 'Immune Adherence Clearance' and Provide a Generic Target to Deplete Pathogens from Septic Patients. *Blood* **2016**, *128*, 1031. [CrossRef]
25. Varki, A.; Gagneux, P. Multifarious roles of sialic acids in immunity. *Ann. N. Y. Acad. Sci.* **2012**, *1253*, 16–36. [CrossRef]
26. Berzuini, A.; Bianco, C.; Migliorini, A.C.; Maggioni, M.; Valenti, L.; Prati, D. Red blood cell morphology in patients with COVID-19-related anaemia. *Blood Transfus* **2021**, *19*, 34–36.
27. Melkumyants, A.; Buryachkovskaya, L.; Lomakin, N.; Antonova, O.; Serebruany, V. Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics? *Thromb. Haemost.* **2022**, *122*, 123–130. [CrossRef]
28. Lakhdari, N.; Tabet, B.; Boudraham, L.; Laoussati, M.; Aissanou, S.; Beddou, L.; Bensalem, S.; Bellik, Y.; Bourmine, L.; Fatmi, S.; et al. Red blood cells injuries and hypersegmented neutrophils in COVID-19 peripheral blood film. *medRxiv* **2020**. [CrossRef]
29. Lam, L.M.; Murphy, S.J.; Kuri-Cervantes, L.; Weisman, A.R.; Ittner, C.A.G.; Reilly, J.P.; Pampena, M.B.; Betts, M.R.; Wherry, E.J.; Song, W.-C.; et al. Erythrocytes Reveal Complement Activation in Patients with COVID-19. *medRxiv* **2020**. [CrossRef]
30. Baker, A.N.; Richards, S.-J.; Guy, C.S.; Congdon, T.R.; Hasan, M.; Zwetsloot, A.J.; Gallo, A.; Lewandowski, J.R.; Stansfeld, P.J.; Straube, A.; et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device. *ACS Cent. Sci.* **2020**, *6*, 2046–2052. [CrossRef]
31. Hao, W.; Ma, B.; Li, Z.; Wang, X.; Gao, X.; Li, Y.; Qin, B.; Shang, S.; Cui, S.; Tan, Z. Binding of the SARS-CoV-2 spike protein to glycans. *Sci. Bull.* **2021**, *66*, 1205–1214. [CrossRef]
32. Shilts, J.; Wright, G.J. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. *bioRxiv* **2020**. [CrossRef] [PubMed]
33. Maeda, N.; Seike, M.; Kon, K.; Shiga, T. Erythrocyte Aggregation as a Determinant of Blood Flow: Effect of pH, Temperature and Osmotic Pressure. In *Oxygen Transport to Tissue X.*; Mochizuki, M., Honig, C.R., Koyama, T., Goldstick, T.K., Bruley, D.F., Eds.; Springer: New York, NY, USA, 1988; pp. 563–570. [CrossRef]
34. Barshtein, G.; Wajnbloom, D.; Yedgar, S. Kinetics of linear rouleaux formation studied by visual monitoring of red cell dynamic organization. *Biophys. J.* **2000**, *78*, 2470–2474. [CrossRef] [PubMed]
35. Magro, C.; Mulvey, J.J.; Berlin, D.; Nuovo, G.; Salvatore, S.; Harp, J.; Baxter-Stoltzfus, A.; Laurence, J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl. Res.* **2020**, *220*, 1–13. [CrossRef] [PubMed]
36. Menter, T.; Haslbauer, J.D.; Nienhold, R.; Savic, S.; Hopfer, H.; Deigendesch, N.; Frank, S.; Turek, D.; Willi, N.; Pargger, H.; et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathology* **2020**, *77*, 198–209. [CrossRef]
37. Becker, R.C. COVID-19 update: COVID-19-associated coagulopathy. *J Thromb. Thrombolysis* **2020**, *50*, 54–67. [CrossRef]
38. Gattinoni, L.; Coppola, S.; Cressoni, M.; Busana, M.; Rossi, S.; Chiumello, D. COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. *Am. J. Respir. Crit. Care Med.* **2020**, *201*, 1299–1300. [CrossRef]
39. Marini, J.J.; Gattinoni, L. Management of COVID-19 Respiratory Distress. *JAMA* **2020**, *323*, 2329–2330. [CrossRef]
40. Grobbelaar, L.M.; Venter, C.; Vlok, M.; Ngoepe, M.; Laubscher, G.J.; Lourens, P.J.; Steenkamp, J.; Kell, D.B.; Pretorius, E. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. *Biosci. Rep.* **2021**, *41*, BSR20210611. [CrossRef]
41. Schultze, B.; Gross, H.J.; Brossmer, R.; Herrler, G. The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant. *J. Virol.* **1991**, *65*, 6232–6237. [CrossRef]
42. Callebaut, P.E.; Pensaert, M.B. Characterization and isolation of structural polypeptides in haemagglutinating encephalomyelitis virus. *J. Gen. Virol.* **1980**, *48*, 193–204. [CrossRef]

43. Aminpour, M.; Cannariato, M.; Safaeeardebili, M.E.; Preto, J.; Moracchiato, A.; Doria, D.; Donato, F.; Zizzi, E.A.; Deriu, M.A.; Scheim, D.E.; et al. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. *Computation* **2022**, *10*, 51. [[CrossRef](#)]
44. Santin, A.D.; Scheim, D.E.; McCullough, P.A.; Yagisawa, M.; Borody, T.J. Ivermectin: A multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19. *New Microbes New Infect.* **2021**, *43*, 100924. [[CrossRef](#)] [[PubMed](#)]
45. Abdool Karim, S.S.; Devnarain, N. Time to Stop Using Ineffective COVID-19 Drugs. *N. Engl. J. Med.* **2022**, *387*, 654–655. [[CrossRef](#)]
46. Shafiee, A.; Teymour Athar, M.M.; Kohandel Gargari, O.; Jafarabady, K.; Siahvoshi, S.; Mozhgani, S.-H. Ivermectin under scrutiny: A systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. *Viol. J.* **2022**, *19*, 102. [[CrossRef](#)] [[PubMed](#)]
47. Zheng, Y.; Zhao, J.; Li, J.; Guo, Z.; Sheng, J.; Ye, X.; Jin, G.; Wang, C.; Chai, W.; Yan, J.; et al. SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate. *Int. J. Biol. Macromol.* **2021**, *193*, 1124–1129. [[CrossRef](#)]
48. Au Sam, H.; Storey Brian, D.; Moore John, C.; Tang, Q.; Chen, Y.-L.; Javaid, S.; Sarioglu, A.F.; Sullivan, R.; Madden Marissa, W.; O’Keefe, R.; et al. Clusters of circulating tumor cells traverse capillary-sized vessels. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 4947–4952.
49. Yamakawa, N.; Vanbeselaere, J.; Chang, L.-Y.; Yu, S.-Y.; Ducrocq, L.; Harduin-Lepers, A.; Kurata, J.; Aoki-Kinoshita, K.F.; Sato, C.; Khoo, K.-H.; et al. Systems glycomics of adult zebrafish identifies organ-specific sialylation and glycosylation patterns. *Nat. Commun.* **2018**, *9*, 4647. [[CrossRef](#)]
50. Colunga Biancatelli, R.M.L.; Solopov, P.A.; Sharlow, E.R.; Lazo, J.S.; Marik, P.E.; Catravas, J.D. The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2021**, *321*, L477–L484. [[CrossRef](#)]
51. Nuovo, G.J.; Magro, C.; Shaffer, T.; Awad, H.; Suster, D.; Mikhail, S.; He, B.; Michaille, J.-J.; Liechty, B.; Tili, E. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. *Ann. Diagn. Pathol.* **2021**, *51*, 151682. [[CrossRef](#)]
52. Perico, L.; Morigi, M.; Galbusera, M.; Pezzotta, A.; Gastoldi, S.; Imberti, B.; Perna, A.; Ruggerenti, P.; Donadelli, R.; Benigni, A.; et al. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. *Front. Immunol.* **2022**, *13*, 827146. [[CrossRef](#)]
53. Fantini, J.; Yahi, N.; Colson, P.; Chahinian, H.; La Scola, B.; Raoult, D. The puzzling mutational landscape of the SARS-2-variant Omicron. *J. Med. Virol.* **2022**, *94*, 2019–2025. [[CrossRef](#)] [[PubMed](#)]
54. Price, L.C.; McCabe, C.; Garfield, B.; Wort, S.J. Thrombosis and COVID-19 pneumonia: The clot thickens! *Eur. Respir. J.* **2020**, *56*, 2001608. [[CrossRef](#)] [[PubMed](#)]
55. Maslo, C.; Friedland, R.; Toubkin, M.; Laubscher, A.; Akaloo, T.; Kama, B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. *JAMA* **2022**, *327*, 583–584. [[CrossRef](#)] [[PubMed](#)]
56. Hui, K.P.Y.; Ho, J.C.W.; Cheung, M.-C.; Ng, K.-C.; Ching, R.H.H.; Lai, K.-L.; Kam, T.T.; Gu, H.; Sit, K.-Y.; Hsin, M.K.Y.; et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature* **2022**, *603*, 715–720. [[CrossRef](#)] [[PubMed](#)]
57. Peacock, T.P.; Brown, J.C.; Zhou, J.; Thakur, N.; Sukhova, K.; Newman, J.; Kugathasan, R.; Yan, A.W.C.; Furnon, W.; De Lorenzo, G.; et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein. *bioRxiv* **2022**. [[CrossRef](#)]
58. D’Agnillo, F.; Walters, K.-A.; Xiao, Y.; Sheng, Z.-M.; Scherler, K.; Park, J.; Gygli, S.; Rosas, L.A.; Sadtler, K.; Kalish, H.; et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. *Sci. Transl. Med.* **2021**, *13*, eabj7790. [[CrossRef](#)]
59. Kumar, S.; Karuppanan, K.; Subramaniam, G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. *J. Med. Virol.* **2022**, *94*, 4780–4791. [[CrossRef](#)]
60. Pascarella, S.; Ciccozzi, M.; Bianchi, M.; Benvenuto, D.; Cauda, R.; Cassone, A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern. *J. Infect.* **2022**, *84*, e62–e63. [[CrossRef](#)]
61. Lam, S.D.; Waman, V.P.; Orengo, C.; Lees, J. Insertions in the SARS-CoV-2 Spike N-Terminal Domain May Aid COVID-19 Transmission. *bioRxiv* **2021**. [[CrossRef](#)]
62. Doria, D.; Santin, A.D.; Tuszyński, J.A.; Scheim, D.E.; Aminpour, M. Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to $\alpha 7nAChR$: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. *BioMedInformatics* **2022**, *2*, 553–564. [[CrossRef](#)]
63. Yagisawa, M.; Omura, S.; Omura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan. (affiliation for both). Personal communication, 2022.
64. Stone, J.C.; Ndarukwa, P.; Scheim, D.E.; Dancis, B.M.; Dancis, J.; Gill, M.G.; Aldous, C. Changes in SpO₂ on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours. *Biologics* **2022**, *2*, 196–210. [[CrossRef](#)]

65. Osman, A.M.; Farouk, S.; Osman, N.M.; Abdrabou, A.M. Longitudinal assessment of chest computerized tomography and oxygen saturation for patients with COVID-19. *Egypt. J. Radiol. Nucl. Med.* **2020**, *51*, 255. [[CrossRef](#)]
66. Metwally, M.I.; Basha, M.A.A.; Zaitoun, M.M.A.; Abdalla, H.M.; Nofal, H.A.E.; Hendawy, H.; Manajrah, E.; Hijazy, R.f.; Akbazli, L.; Negida, A.; et al. Clinical and radiological imaging as prognostic predictors in COVID-19 patients. *Egypt. J. Radiol. Nucl. Med.* **2021**, *52*, 100. [[CrossRef](#)]
67. Aoki, R.; Iwasawa, T.; Hagiwara, E.; Komatsu, S.; Utsunomiya, D.; Ogura, T. Pulmonary vascular enlargement and lesion extent on computed tomography are correlated with COVID-19 disease severity. *Jpn. J. Radiol.* **2021**, *39*, 451–458. [[CrossRef](#)] [[PubMed](#)]
68. Ding, X.; Xu, J.; Zhou, J.; Long, Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. *Eur. J. Radiol.* **2020**, *127*, 109009. [[CrossRef](#)] [[PubMed](#)]
69. Wang, Y.; Dong, C.; Hu, Y.; Li, C.; Ren, Q.; Zhang, X.; Shi, H.; Zhou, M. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology* **2020**, *296*, E55–E64. [[CrossRef](#)]
70. Quispe-Cholan, A.; Anticona-De-La-Cruz, Y.; Cornejo-Cruz, M.; Quispe-Chirinos, O.; Moreno-Lazaro, V.; Chavez-Cruzado, E. Tomographic findings in patients with COVID-19 according to evolution of the disease. *Egypt. J. Radiol. Nucl. Med.* **2020**, *51*, 215. [[CrossRef](#)]
71. Annunziata, A.; Coppola, A.; Carannante, N.; Simioli, F.; Lanza, M.; Di Micco, P.; Fiorentino, G. Home Management of Patients with Moderate or Severe Respiratory Failure Secondary to COVID-19, Using Remote Monitoring and Oxygen with or without HFNC. *Pathogens* **2021**, *10*, 413. [[CrossRef](#)]
72. Gupta, Y.; Maciorowski, D.; Zak, S.E.; Kulkarni, C.V.; Herbert, A.S.; Durvasula, R.; Fareed, J.; Dye, J.M.; Kempaiah, P. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. *Int. J. Biol. Macromol.* **2021**, *183*, 203–212. [[CrossRef](#)]
73. Li, C.; Chen, Y.; Zhao, Y.; Lung, D.C.; Ye, Z.; Song, W.; Liu, F.-F.; Cai, J.-P.; Wong, W.-M.; Yip, C.C.-Y.; et al. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model. *Clin. Infect. Dis.* **2022**, *74*, 1933–1950. [[CrossRef](#)]
74. Trougakos, I.P.; Terpos, E.; Alexopoulos, H.; Politou, M.; Paraskevis, D.; Scorilas, A.; Kastiris, E.; Andreakos, E.; Dimopoulos, M.A. Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis. *Trends Mol. Med.* **2022**, *28*, 542–554. [[CrossRef](#)] [[PubMed](#)]
75. Cosentino, M.; Marino, F. The spike hypothesis in vaccine-induced adverse effects: Questions and answers. *Trends Mol. Med.* **2022**, *28*, 797–799. [[CrossRef](#)] [[PubMed](#)]
76. Cognetti, J.S.; Miller, B.L. Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination. *Sensors* **2021**, *21*, 5857. [[CrossRef](#)] [[PubMed](#)]
77. Ogata, A.F.; Cheng, C.A.; Desjardins, M.; Senussi, Y.; Sherman, A.C.; Powell, M.; Novack, L.; Von, S.; Li, X.; Baden, L.R.; et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. *Clin. Infect. Dis.* **2022**, *74*, 715–718. [[CrossRef](#)]
78. Röltgen, K.; Nielsen, S.C.A.; Silva, O.; Younes, S.F.; Zaslavsky, M.; Costales, C.; Yang, F.; Wirz, O.F.; Solis, D.; Hoh, R.A.; et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. *Cell* **2022**, *185*, 1025–2040. [[CrossRef](#)]
79. Giovannini, F. Dark Field Microscopic Analysis on the Blood of 1,006 Symptomatic Persons After Anti-COVID mRNA Injections from Pfizer/BioNTech or Moderna. *Int. J. Vaccine Theory Pract. Res.* **2022**, *2*, 385–444.
80. Mansanguan, S.; Charunwatthana, P.; Piyaphanee, W.; Dechkhajorn, W.; Poolcharoen, A.; Mansanguan, C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. *Trop. Med. Infect. Dis.* **2022**, *7*, 196. [[CrossRef](#)]
81. MacMillan, C. The Omicron booster: Your Questions Answered. *Yale Medicine News*, 27 October 2022. Available online: <https://www.yalemedicine.org/news/omicron-booster-covid-19> (accessed on 3 November 2022).
82. Klotz, U.; Ogbuokiri, J.E.; Okonkwo, P.O. Ivermectin binds avidly to plasma proteins. *Eur. J. Clin. Pharmacol.* **1990**, *39*, 607–608. [[CrossRef](#)]
83. Thairu, Y.; Babalola, O.E.; Ajayi, A.A.; Ndanusa, Y.; Ogedengbe, J.O.; Omede, O. A comparison of Ivermectin and Non Ivermectin based regimen for COVID-19 in Abuja: Effects on virus clearance, Days-to-Discharge and Mortality. *Res. Sq.* **2022**. [[CrossRef](#)]
84. Babalola, O.E.; Bingham University, Jos/Karu, Nigeria. Personal communication, 2022. This communication provided deidentified patient level data for SpO2 changes post-treatment from two studies which he coauthored (Thairu et al., 2022 and Babalola et al., 2021 as cited), one using standard treatment excluding IVM (Thairu et al., 2022) and the other including IVM in the treatment regimen (Babalola et al., 2021), for those values obtained exclusively on room air and with pre-treatment SpO2 values $\leq 93\%$.
85. Babalola, O.E.; Ndanusa, Y.; Adesuyi, A.; Ogedengbe, O.J.; Thairu, Y.; Ogu, O. A Randomized Controlled Trial of Ivermectin Monotherapy Versus HCQ, IVM, and AZ Combination Therapy in COVID-19 Patients in Nigeria. *J. Infect. Dis. Epidemiol.* **2021**, *7*, 233. [[CrossRef](#)]
86. Hazan, S.; Dave, S.; Gunaratne, A.W.; Dolai, S.; Clancy, R.L.; McCullough, P.A.; Borody, T.J. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. *Future Microbiol.* **2022**, *17*, 339–350. [[CrossRef](#)] [[PubMed](#)]
87. Colson, P.; Levasseur, A.; Delerce, J.; Pinault, L.; Dudouet, P.; Devaux, C.; Fournier, P.E.; La Scola, B.; Lagier, J.C.; Raoult, D. Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage. *Clin. Microbiol. Infect.* **2021**, *27*, 1352.e1–1352.e5. [[CrossRef](#)] [[PubMed](#)]

88. Jaafar, R.; Boschi, C.; Aherfi, S.; Bancod, A.; Le Bideau, M.; Edouard, S.; Colson, P.; Chahinian, H.; Raoult, D.; Yahi, N.; et al. High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. *Viruses* **2021**, *13*, 2177. [[CrossRef](#)] [[PubMed](#)]
89. Boschi, C.; Colson, P.; Bancod, A.; Moal, V.; La Scola, B. Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC). *Clin. Infect. Dis.* **2022**, *75*, e534–e535. [[CrossRef](#)] [[PubMed](#)]
90. Rambaut, A.; Holmes, E.C.; O’Toole, Á.; Hill, V.; McCrone, J.T.; Ruis, C.; du Plessis, L.; Pybus, O.G. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat. Microbiol.* **2020**, *5*, 1403–1407. [[CrossRef](#)]
91. Townsend, A.; Rijal, P.; Xiao, J.; Tan, T.K.; Huang, K.A.; Schimanski, L.; Huo, J.; Gupta, N.; Rahikainen, R.; Matthews, P.C.; et al. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. *Nat. Commun.* **2021**, *12*, 1951. [[CrossRef](#)]
92. Fantini, J.; Yahi, N.; Azzaz, F.; Chahinian, H. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks. *J. Infect.* **2021**, *83*, 197–206. [[CrossRef](#)] [[PubMed](#)]
93. Kim, D.E.; Chivian, D.; Baker, D. Protein structure prediction and analysis using the Robetta server. *Nucleic Acids Res.* **2004**, *32*, W526–W531. [[CrossRef](#)]
94. Guex, N.; Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. *Electrophoresis* **1997**, *18*, 2714–2723. [[CrossRef](#)]